Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it?

Leukemia

Volumn 28, Issue 11, 2014, Pages 2267-2270

  Barosi, G ^a   Zhang, M J ^b   Gale, R Peter ^c  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE; PYRAZOLE DERIVATIVE; RUXOLITINIB;

ANTAGONISTS AND INHIBITORS; FOLLOW UP; HUMAN; MORTALITY; MYELOPROLIFERATIVE DISORDERS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE;

FOLLOW-UP STUDIES; HUMANS; JANUS KINASES; MYELOPROLIFERATIVE DISORDERS; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE;

EID: 84922334216     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.220     Document Type: Letter

References (15)

1. Pardanani A, Vannucchi AM, Passamonti F, Cervantes F, Barbui T, Tefferi A. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia 2011; 25: 218–225. DOI: 10.1038/leu.2010.269
2. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010; 363: 1117–1127. DOI: 10.1056/NEJMoa1002028
3. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799–807. DOI: 10.1056/NEJMoa1110557
4. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012; 366: 787–798. DOI: 10.1056/NEJMoa1110556
5. Mesa R, Gale RP. Hypothesis: How do JAK2-inhibitors work in myelofibrosis. Leuk Res 2009; 33: 1156–1157. DOI: 10.1016/j.leukres.2009.04.011
6. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 2013; 98: 1865–1871. DOI: 10.3324/haematol.2013.092155
7. Cervantes F, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Sirulnik A, Stalbovskaya V et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013; 122: 4047–4053. DOI: 10.1182/blood-2013-02-485888
8. Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 2012; 120: 1202–1209. DOI: 10.1182/blood-2012-02-414631
9. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115: 1703–1708. DOI: 10.1182/blood-2009-09-245837
10. Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in Myelofibrosis. N Engl J Med 2011; 365: 1455–1457. DOI: 10.1056/NEJMc1109555
11. Little RJ, D'Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT et al. The prevention and treatment of missing data in clinical trials. N Engl J Med 2012; 367: 1355–1360. DOI: 10.1056/NEJMsr1203730
12. Hernán MA, Hernández-Díaz S, Robins JM. Randomized trials analyzed as observational studies. Ann Intern Med 2013; 159: 560–562.
13. Passamonti F, Maffioli M, Cervantes F, Vannucchi AM, Morra E, Barbui T et al. Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood 2014; 123: 1833–1835. DOI: 10.1182/blood-2013-12-544411
14. Xu Z, Gale RP, Zhang Y, Qin T, Chen H, Zhang P et al. Unique features of primary myelofibrosis in Chinese. Blood 2012; 119: 2469–2473. DOI: 10.1182/blood-2011-11-389866
15. Liberati A. Need to realign patient-oriented and commercial and academic research. Lancet 2011; 378: 1777–1778. DOI: 10.1016/S0140-6736(11)61772-8